PSNL · Personalis, Inc. · Executive Compensation
$15.98
+0.10 (+0.63%)
At close · Oct 27
Return incl. dividend (before tax)
Q1 2026 earnings call transcript
Market Cap
$1.70B
Shares
106.80M
Volume · Oct 27
1.83M
Avg daily vol (3M)
2.78M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Christopher Hall | Chief Executive Officer and Director | $3,505,978 |
| Christopher M. Hall | CEO | $3,505,978 |
| Aaron L. Tachibana | CFO | $1,608,300 |
| Aaron Tachibana | Chief Financial Officer and Chief Operating Officer | $1,608,300 |
| Richard Chen | M.D., M.S. President, Executive Vice President, Research and Development and Chief Medical Officer | $1,589,150 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Christopher M. Hall | CEO | $1,535,960 |
| Christopher Hall | President, Chief Executive Officer, and Director | $1,535,960 |
| Aaron Tachibana | Chief Financial Officer and Chief Operating Officer | $1,011,594 |
| Aaron L. Tachibana | CFO | $1,011,594 |
| Richard Chen | M.D., M.S. Executive Vice President, Research and Development and Chief Medical Officer | $989,394 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Christopher M. Hall | CEO | $1,726,790 |
| Christopher Hall | President, Chief Executive Officer, and Director | $1,726,790 |
| Aaron Tachibana | Chief Financial Officer and Chief Operating Officer | $1,669,420 |
| Aaron L. Tachibana | CFO | $1,669,420 |
| Richard Chen | M.D., M.S. Executive Vice President, Research and Development and Chief Medical Officer | $1,277,500 |
| Stephen Moore | Chief Legal Officer and Corporate Secretary | $674,279 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| John West | Former President, Chief Executive Officer, and Director | $5,615,508 |
| Christopher Hall | President, Chief Executive Officer, and Director | $1,212,507 |
| Christopher M. Hall | CEO | $1,212,507 |
| Richard Chen | M.D., M.S. Executive Vice President, Research and Development and Chief Medical Officer | $690,576 |
| Stephen Moore | Chief Legal Officer and Corporate Secretary | $681,694 |
| Aaron L. Tachibana | CEO | $676,010 |
| Aaron Tachibana | Chief Financial Officer, Chief Operating Officer, and former interim Chief Executive Officer | $676,010 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| John West | Former President, Chief Executive Officer, and Director | $4,929,200 |
| Richard Chen | M.D., M.S. Executive Vice President, Research and Development and Chief Medical Officer | $3,056,713 |
| Aaron Tachibana | Chief Financial Officer, Chief Operating Officer, and former interim Chief ExecutiveOfficer | $2,963,050 |
| Aaron L. Tachibana | CFO | $2,963,050 |
| Christopher M. Hall | CEO | — |
| Christopher Hall | President, Chief Executive Officer, and Director | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| John West | President, Chief Executive Officer, and Director | $3,383,138 |
| Aaron Tachibana | Chief Financial Officer | $1,514,519 |
| Aaron L. Tachibana | CFO | $1,514,519 |
| Richard Chen | M.D., M.S. Chief Scientific Officer | $1,436,461 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Aaron L. Tachibana | CFO | $3,003,507 |
| Aaron Tachibana | Chief Financial Officer | $3,003,507 |
| John West | President, Chief Executive Officer, and Director | $981,991 |
| Richard Chen | M.D., M.S. Chief Scientific Officer | $632,351 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| John West | President, Chief Executive Officer, and Director | $1,491,452 |
| Richard Chen | M.D., M.S. Chief Scientific Officer | $840,965 |
| Aaron Tachibana | Chief Financial Officer | — |
| Aaron L. Tachibana | CFO | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Richard Chen | President | Appointed | 2026-03-17 |
| Kenneth Widder | Class II director | Appointed | 2023-06-14 |
| Alan Colowick | member of the Company's Board of Directors | Resigned | 2023-06-14 |
| Christopher Hall | Class II director | Appointed | 2023-03-08 |
| Christopher Hall | Chief Executive Officer | Appointed | 2023-03-08 |
| Richard Chen | Executive Vice President, R&D | Appointed | 2023-03-08 |
| Aaron Tachibana | Chief Operating Officer | Appointed | 2023-03-08 |
| Christopher Hall | President | Appointed | 2022-12-14 |
| Aaron Tachibana | interim Chief Executive Officer | Appointed | 2022-12-14 |
| John West | member of the board of directors | Retired | 2022-12-14 |
| John West | Chief Executive Officer | Retired | 2022-12-14 |
Leadership
- Aaron Tachibana CEO, CFO, COO
- Christopher Hall CEO, Board Member
- Christopher M. Hall CEO, Board Member
- Karin Eastham Chairman
- Aaron L. Tachibana CFO
- Stephen Moore General Counsel
- Kenneth Widder Board Member
- Olivia K. Bloom Board Member
- Woodrow (Woody) A. Myers, Jr., M.D. Board Member
- Woodrow A. Myers Board Member
Key facts
CIK
1527753
CUSIP
71535D106
13F (30d)
20 filings
20 filers
Visit website
Investor relations